Results 111 to 120 of about 11,301 (165)

PCSK9 inhibitors - clinical applications.

Australian prescriber
The enzyme PCSK9 has an important role in regulating low-density lipoprotein (LDL) receptors and concentrations of LDL cholesterol. Inhibiting this enzyme could therefore reduce the incidence of ischaemic heart disease. The monoclonal antibodies alirocumab, evolocumab and bococizumab are directed against PCSK9 and inhibit its activity.
openaire   +2 more sources

Sustaining the Promise of PCSK9 Inhibitors: Lessons from Real-World Adherence in China. [PDF]

J Atheroscler Thromb
Nohara A.
europepmc   +1 more source

PCSK9 inhibitors are go [PDF]

Nature Reviews Drug Discovery, 2015
openaire   +1 more source

Effectiveness of PCSK9 inhibitors versus statins in type 2 diabetes and dyslipidemia: a propensity-matched study. [PDF]

Front Endocrinol (Lausanne)
Wu JY, Lin YM, Hsu WH, Liu T, Tsai YW, Huang PY, Chuang MH, Yu T, Lai CC.   +8 more
europepmc   +1 more source

Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects. [PDF]

J Transl Med
Bosco G, Di Giacomo Barbagallo F, Di Marco M, Scilletta S, Miano N, Pistritto C, Tiralongo M, Di Stefano C, Pennisi G, De Francesco EM, Malaguarnera R, Di Pino A, Piro S, Scicali R.   +13 more
europepmc   +1 more source

PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre observational study. [PDF]

Sci Rep
Akhtar W, Khan T, Neves E, Browne C, Tawil M, Lyster H, Dar O.   +6 more
europepmc   +1 more source

Paradoxical LDL-C Increase after Switching from PCSK9 Inhibitors to Inclisiran: A Real-World Case Series. [PDF]

Acta Cardiol Sin
Chua SK, Hung HF, Jong BH, Chen LC.
europepmc   +1 more source

Medical and Financial Consequences of Using PCSK9 Inhibitors for Managing Hypercholesterolemia in Saudi Arabia: A Historical Cohort Study. [PDF]

Healthcare (Basel)
AlRuthia Y, Almutairi KK, Aljammaz NA, Alsuwayegh A, Alanazi MA, AlSulaiman RF, Alfaori TM, Alabdan N.   +7 more
europepmc   +1 more source

Hypercholesterolemia Successfully Treated With Two Different PCSK9 Inhibitors in a Patient With Glycogen Storage Disease IXd: Phosphorylase Kinase Deficiency. [PDF]

J Lipid Atheroscler
Huynh T, Nguyen H, Nguyen M.
europepmc   +1 more source

Outcomes of PCSK9 Inhibitors

JACC: Advances, 2023
openaire   +1 more source